BeiGene, Ltd. Interest Expense 2011-2025 | BGNE

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense BeiGene, Ltd.

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-12.6 M	308 M	-224 M	15.9 M	37.5 M	7.17 M	1.99 M	11.5 M	-972 K	1.22 M	600 K	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
308 M	-224 M	13.3 M

Quarterly Interest Expense BeiGene, Ltd.

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-19 M	8.17 M	3.95 M	-	11.3 M	-12 M	1.76 M	-	337 M	-63.8 M	18.3 M	-	-126 M	-130 M	12 M	-	31.5 M	-867 K	-4.12 M	-	5.71 M	20 M	3.68 M	-	-1.82 M	-878 K	1.73 M	-	1.58 M	75 K	729 K	-	1.1 M	-475 K	913 K	-	284 K	141 K	204 K	-	300 K	273 K	267 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
337 M	-130 M	3.1 M

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Pharming Group N.V. PHAR	10 K	$ 17.91	-1.0 %	$ 7.59 B	Niderland
InflaRx N.V. IFRX	885	$ 1.09	-4.82 %	$ 152 M	Germany
Alpine Immune Sciences ALPN	476 K	-	-	$ 2.17 B	USA
Arbutus Biopharma Corporation ABUS	459 K	$ 4.78	-0.31 %	$ 793 M	Canada
Aclaris Therapeutics ACRS	2.95 M	$ 3.03	-0.49 %	$ 234 M	USA
Aeglea BioTherapeutics AGLE	-20.7 M	-	-	$ 1.01 B	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
AlloVir ALVR	1.19 M	-	4.14 %	$ 49.1 M	USA
Ascendis Pharma A/S ASND	65.5 M	$ 209.39	-1.61 %	$ 5 B	Danmark
Ampio Pharmaceuticals AMPE	-5.01 K	-	-11.43 %	$ 502 K	USA
Applied Molecular Transport AMTI	-4 K	-	-	$ 10.1 M	USA
Aptevo Therapeutics APVO	472 K	$ 0.6	-35.8 %	$ 166 K	USA
Avenue Therapeutics ATXI	294 K	-	-52.27 %	$ 4.45 M	USA
Autolus Therapeutics plc AUTL	9.29 M	$ 1.66	-1.49 %	$ 424 M	Britain
Alterity Therapeutics Limited ATHE	2.28 K	$ 3.12	0.81 %	$ 7.51 B	Australia
BioDelivery Sciences International BDSI	-6 K	-	-4.8 %	$ 255 M	USA
Athersys ATHX	103 K	-	3.77 %	$ 22.4 M	USA
BioVie BIVI	4.3 M	$ 1.2	-5.51 %	$ 1.77 M	USA
ARCA biopharma ABIO	9 K	-	1052.0 %	$ 415 M	USA
Bellicum Pharmaceuticals BLCM	2.66 M	-	-9.72 %	$ 5.89 M	USA
Can-Fite BioPharma Ltd. CANF	227 K	$ 0.22	24.46 %	$ 479 M	Israel
Adaptimmune Therapeutics plc ADAP	-807 K	-	-15.15 %	$ 60.3 M	Britain
Berkeley Lights BLI	910 K	-	-7.31 %	$ 87 M	USA
Albireo Pharma ALBO	3.69 M	-	-0.23 %	$ 916 M	USA
Amphastar Pharmaceuticals AMPH	4.08 M	$ 27.09	1.04 %	$ 1.31 B	USA
Calithera Biosciences CALA	2.65 M	-	-10.95 %	$ 876 K	USA
bluebird bio BLUE	16.4 M	-	-	$ 546 M	USA
Zai Lab Limited ZLAB	2.25 M	$ 18.4	-0.97 %	$ 18.2 B	China
Catalyst Biosciences CBIO	1.04 M	$ 12.33	-0.29 %	$ 812 M	USA
Arena Pharmaceuticals ARNA	4.16 M	-	-6.81 %	$ 3.04 B	USA
Acer Therapeutics ACER	432 K	-	2.71 %	$ 14 M	USA
Axon Enterprise AXON	286 M	$ 584.81	-1.07 %	$ 44.3 B	USA
Aytu BioScience AYTU	-512 K	$ 2.44	-3.56 %	$ 15.3 M	USA
ChromaDex Corporation CDXC	3 K	-	-0.88 %	$ 598 M	USA
Certara CERT	-15.5 M	$ 8.9	-0.17 %	$ 1.43 B	USA
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA